Altimmune (ALT) Restructuring Costs (2015)
Altimmune (ALT) posted quarterly Restructuring Costs of $26886.0 for Q4 2015, down 93.64% quarter-over-quarter from $422482.0 in Q3 2015.
Analysis
Altimmune (ALT) Restructuring Costs (2015) Analysis & Trends
Altimmune (ALT) has reported Restructuring Costs for 1 consecutive years, with $26886.0 the latest figure, recorded in Q4 2015.
- In Q4 2015, Restructuring Costs changed N/A year-over-year to $26886.0; the TTM figure through Sep 2016 stood at $26886.0 (changed N/A YoY), while the FY2015 annual figure was $2.5 million, changed N/A from the prior year.
- Restructuring Costs declined to $26886.0 in Q4 2015 per ALT's latest filing, from $422482.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $2.1 million in Q1 2015 and bottomed at $26886.0 in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Altimmune | 625.87 Mn | 625.87 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2015 | 26,886.00 |
| Sep 30, 2015 | 422,482.00 |
| Jun 30, 2015 | 35,982.00 |
| Mar 31, 2015 | 2.06 Mn |